Cytomedix Inc. New (CMXI) 0.3930 $CMXI
Cytomedix to Present at the Rodman & Renshaw Global Investment Conference
GlobeNewswire - Tue Sep 02, 8:58AM CDT
Cytomedix (OTC:CMXI), a pioneer in biodynamic therapies, today announced that Martin Rosendale, CEO, will present a corporate overview at the 16 Annual Rodman & Renshaw Global Investment conference, being held September 8-10, 2014 at the New York Palace Hotel in New York, NY.
What Makes OncoMed Pharmaceuticals (OMED) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 7:28AM CDT
OncoMed Pharmaceuticals is a stock to drop as it has witnessed negative trend in earnings estimate revisions and has seen its price decline significantly.
Cytomedix Partners With Net Health to Expand CED Data Collection Capabilities to Approximately 400 Additional Wound Care Centers
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Net Health's WoundExpert(R) Electronic Medical Record ("EMR"
Software to Empower CED Study of AutoloGel(TM)
Pick's Disease Global Clinical Trials Review, H1, 2014
M2 - Fri Aug 15, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qq6xsf/picks_disease) has announced the addition of the "Pick's Disease Global Clinical Trials Review, H1, 2014" report to their offering. Pick's Disease Global Clinical Trials Review, H1, 2014" provides data on the Pick's Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pick's Disease It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pick's Disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Sanofi - Johnson & Johnson - Diaxonhit S.A. - Cytomedix, Inc. Clinical Trial Overview of Top Institutes / Government - National Institute of Neurological Disorders and Stroke - University of California, San Francisco - Pusan National University Hospital - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Lawson Health Research Institute - Fairview University Medical Center - Baycrest - Masonic Cancer Center - Johns Hopkins University - University of Louisville For more information visit http://www.researchandmarkets.com/research/qq...ks_disease
Cytomedix Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 3:05PM CDT
Updates on AutoloGel(TM) Commercialization Efforts
Cytomedix to Report Second Quarter 2014 Financial Results on Thursday, August 14, 2014
GlobeNewswire - Mon Aug 11, 7:45AM CDT
Cytomedix (OTC:CMXI) announced today that it will report financial results for the second quarter of 2014 on Thursday, August 14, 2014, after the close of market.
Malignant Glioma - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ljjnrf/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Malignant Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - ZIOPHARM Oncology, Inc. - Cytomedix, Inc. - Stemline Therapeutics, Inc. - EirGen Pharma Ltd. For more information visit http://www.researchandmarkets.com/research/lj...ant_glioma
Cytomedix receives USD26m from second tranche under its convertible debt financing
M2 - Fri Jun 27, 4:54AM CDT
Regenerative therapies company Cytomedix (Other OTC:CMXI) said on Thursday that it has closed the second tranche for gross proceeds of USD26m under its convertible debt financing with certain investment funds managed by Deerfield Management Company.
Cytomedix Completes the Second Tranche of the $35 Million Convertible Debt Financing With Deerfield Management Company
GlobeNewswire - Thu Jun 26, 7:14AM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today announced receipt, following satisfaction of closing conditions, of the second tranche of the gross proceeds in the amount of $26 million (for a total $35 million) in convertible debt financing from certain investment funds managed by Deerfield Management Company, L.P. Under the terms of the Facility Agreement dated as of March 31, 2014, Deerfield agreed to provide to the Company up to $35 million in financing through a senior secured convertible debt facility. The commitment consisted of two separate tranches, of which the first $9 million was received upon initial closing of the transaction on March 31, 2014. The second tranche in the gross amount of $26 million was completed as anticipated. As previously disclosed, the notes have a fixed conversion price of $0.52 per share. Following the retirement of debt and payment of certain expenses associated with the closing of the second tranche, the net proceeds to the Company were approximately $22.1 million.
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rtp9gn/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - AstraZeneca PLC - Athersys, Inc. - CardioVascular BioTherapeutics, Inc. - Sigma-Tau S.p.A. - Celgene Corporation - Cytokinetics, Incorporated - Cytomedix, Inc. - ReNeuron Group plc - Genovate Biotechnology Co., LTD. - Proteon Therapeutics, Inc. - Diffusion Pharmaceuticals LLC - Theravasc, Inc. - ViroMed Co., Ltd. - DNAVEC Corporation - miRagen Therapeutics, Inc. - RegenoCELL Therapeutics, Inc. - Provasculon, Inc. - Multi Gene Vascular Systems Ltd - Cardiolynx AG - Exodos Life Science Limited - Recardio GmbH For more information visit http://www.researchandmarkets.com/research/rtp9gn/peripheral
Cytomedix, Inc. - Product Pipeline Review - 2014
PR Newswire - Tue Jun 17, 3:44PM CDT
Reportbuyer.com has added a new market research report:
Deerfield Announces a $35 Million Dollar Investment Commitment to Cytomedix, Inc.
Business Wire - Mon Mar 31, 3:45PM CDT
Deerfield Management Company announced today that it has committed to invest up to $35 million dollars in Cytomedix, Inc. (OTCQX: CMXI) through a senior secured convertible debt facility with warrants.
Cytomedix Announces Senior Management Appointments
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Industry Veteran and Wound Care Commercial Expert Dean Tozer Appointed as Executive Vice President and Chief Commercial Officer
Cytomedix Reports 2013 Fourth Quarter and Full Year Financial Results; Announces Up to $35 Million Convertible Debt Financing With Deerfield Management Company
GlobeNewswire - Mon Mar 31, 3:37PM CDT
$2 Million Additional Equity Investment with Anson Group
Cytomedix to Host Fourth Quarter & Fiscal Year End 2013 Financial Results Conference Call on Tuesday, April 1, 2014
GlobeNewswire - Tue Mar 25, 7:17AM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today that it will release financial results for the three- and twelve-month period ended December 31, 2013, after the close of the market on Monday, March 31, 2014.
Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST
Malignant Glioma - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/zr3vfj/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2013" report to their offering. 'Malignant Glioma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Malignant Glioma Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles Eir-060 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile Carboxyamidotriazole Orotate - Drug Profile SL-701 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile SAR-245409 - Drug Profile WT1 Peptide Vaccine - Drug Profile celecoxib Dendritic Cell Vaccine [temozolomide] Radiation Therapy - Drug Profile Dendritic Cell Vaccine - Drug Profile Peptide Vaccine [sargramostim] - Drug Profile ALD-451 - Drug Profile First Generation Attenuated Strain Of Reovirus - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Sanofi Cytomedix, Inc. Stemline Therapeutics, Inc. EirGen Pharma Ltd. Tactical Therapeutics, Inc For more information visit http://www.researchandmarkets.com/research/zr...ant_glioma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
W2 Energy Reports on 2013 and Looks Forward to 2014
Marketwire - Tue Jan 14, 1:06PM CST
W2 Energy, Inc. (OTC Pink: WTWO) is pleased to report on 2013's past year progress and looking forward into 2014.
Better Increase, Best Family, Fun Day for Eskom Workers [press release]
All Africa Global Media - Tue Jan 14, 12:38PM CST
The National Union of Mineworkers (NUM) is extremely saddened by Eskom for its failure to pay the salary increase of its employees "who have been unilaterally declared essential service by Eskom Management".
Cytomedix Announces Completion of RECOVER-Stroke Trial Enrollment and Update on Bright Cell Technology
Marketwire - Mon Jan 06, 7:02AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today the completed enrollment of the RECOVER-Stroke trial. Based on an interim resizing analysis that was performed on the existing population of all subjects who have reached the treatment plus 90 days primary efficacy endpoint, it was concluded that the ongoing RECOVER-Stroke trial is adequately powered based on pre-specified assumptions at the current enrollment of 48 patients. Consequently, additional screening and enrollment of new patient subjects will cease immediately. The Company expects to announce the top line clinical results in May 2014 when they become available.
Cytomedix to Present at the Rodman & Renshaw Global Investment Conference
GlobeNewswire - Tue Sep 02, 8:58AM CDT
Cytomedix (OTC:CMXI), a pioneer in biodynamic therapies, today announced that Martin Rosendale, CEO, will present a corporate overview at the 16 Annual Rodman & Renshaw Global Investment conference, being held September 8-10, 2014 at the New York Palace Hotel in New York, NY.
What Makes OncoMed Pharmaceuticals (OMED) a Strong Sell? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 7:28AM CDT
OncoMed Pharmaceuticals is a stock to drop as it has witnessed negative trend in earnings estimate revisions and has seen its price decline significantly.
Cytomedix Partners With Net Health to Expand CED Data Collection Capabilities to Approximately 400 Additional Wound Care Centers
GlobeNewswire - Wed Aug 20, 8:29AM CDT
Net Health's WoundExpert(R) Electronic Medical Record ("EMR"
Software to Empower CED Study of AutoloGel(TM) Pick's Disease Global Clinical Trials Review, H1, 2014
M2 - Fri Aug 15, 4:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qq6xsf/picks_disease) has announced the addition of the "Pick's Disease Global Clinical Trials Review, H1, 2014" report to their offering. Pick's Disease Global Clinical Trials Review, H1, 2014" provides data on the Pick's Disease clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pick's Disease It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pick's Disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - Sanofi - Johnson & Johnson - Diaxonhit S.A. - Cytomedix, Inc. Clinical Trial Overview of Top Institutes / Government - National Institute of Neurological Disorders and Stroke - University of California, San Francisco - Pusan National University Hospital - Eunice Kennedy Shriver National Institute of Child Health and Human Development - Lawson Health Research Institute - Fairview University Medical Center - Baycrest - Masonic Cancer Center - Johns Hopkins University - University of Louisville For more information visit http://www.researchandmarkets.com/research/qq...ks_disease
Cytomedix Reports Second Quarter 2014 Financial Results
GlobeNewswire - Thu Aug 14, 3:05PM CDT
Updates on AutoloGel(TM) Commercialization Efforts
Cytomedix to Report Second Quarter 2014 Financial Results on Thursday, August 14, 2014
GlobeNewswire - Mon Aug 11, 7:45AM CDT
Cytomedix (OTC:CMXI) announced today that it will report financial results for the second quarter of 2014 on Thursday, August 14, 2014, after the close of market.
Malignant Glioma - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ljjnrf/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Malignant Glioma - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Malignant Glioma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Sanofi - ZIOPHARM Oncology, Inc. - Cytomedix, Inc. - Stemline Therapeutics, Inc. - EirGen Pharma Ltd. For more information visit http://www.researchandmarkets.com/research/lj...ant_glioma
Cytomedix receives USD26m from second tranche under its convertible debt financing
M2 - Fri Jun 27, 4:54AM CDT
Regenerative therapies company Cytomedix (Other OTC:CMXI) said on Thursday that it has closed the second tranche for gross proceeds of USD26m under its convertible debt financing with certain investment funds managed by Deerfield Management Company.
Cytomedix Completes the Second Tranche of the $35 Million Convertible Debt Financing With Deerfield Management Company
GlobeNewswire - Thu Jun 26, 7:14AM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, today announced receipt, following satisfaction of closing conditions, of the second tranche of the gross proceeds in the amount of $26 million (for a total $35 million) in convertible debt financing from certain investment funds managed by Deerfield Management Company, L.P. Under the terms of the Facility Agreement dated as of March 31, 2014, Deerfield agreed to provide to the Company up to $35 million in financing through a senior secured convertible debt facility. The commitment consisted of two separate tranches, of which the first $9 million was received upon initial closing of the transaction on March 31, 2014. The second tranche in the gross amount of $26 million was completed as anticipated. As previously disclosed, the notes have a fixed conversion price of $0.52 per share. Following the retirement of debt and payment of certain expenses associated with the closing of the second tranche, the net proceeds to the Company were approximately $22.1 million.
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014
M2 - Tue Jun 24, 4:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rtp9gn/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - AstraZeneca PLC - Athersys, Inc. - CardioVascular BioTherapeutics, Inc. - Sigma-Tau S.p.A. - Celgene Corporation - Cytokinetics, Incorporated - Cytomedix, Inc. - ReNeuron Group plc - Genovate Biotechnology Co., LTD. - Proteon Therapeutics, Inc. - Diffusion Pharmaceuticals LLC - Theravasc, Inc. - ViroMed Co., Ltd. - DNAVEC Corporation - miRagen Therapeutics, Inc. - RegenoCELL Therapeutics, Inc. - Provasculon, Inc. - Multi Gene Vascular Systems Ltd - Cardiolynx AG - Exodos Life Science Limited - Recardio GmbH For more information visit http://www.researchandmarkets.com/research/rtp9gn/peripheral
Cytomedix, Inc. - Product Pipeline Review - 2014
PR Newswire - Tue Jun 17, 3:44PM CDT
Reportbuyer.com has added a new market research report:
Deerfield Announces a $35 Million Dollar Investment Commitment to Cytomedix, Inc.
Business Wire - Mon Mar 31, 3:45PM CDT
Deerfield Management Company announced today that it has committed to invest up to $35 million dollars in Cytomedix, Inc. (OTCQX: CMXI) through a senior secured convertible debt facility with warrants.
Cytomedix Announces Senior Management Appointments
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Industry Veteran and Wound Care Commercial Expert Dean Tozer Appointed as Executive Vice President and Chief Commercial Officer
Cytomedix Reports 2013 Fourth Quarter and Full Year Financial Results; Announces Up to $35 Million Convertible Debt Financing With Deerfield Management Company
GlobeNewswire - Mon Mar 31, 3:37PM CDT
$2 Million Additional Equity Investment with Anson Group
Cytomedix to Host Fourth Quarter & Fiscal Year End 2013 Financial Results Conference Call on Tuesday, April 1, 2014
GlobeNewswire - Tue Mar 25, 7:17AM CDT
Cytomedix, Inc. (OTCQX:CMXI), a leading developer of biologically active regenerative therapies, announced today that it will release financial results for the three- and twelve-month period ended December 31, 2013, after the close of the market on Monday, March 31, 2014.
Yale prepares for atom smasher's farewell, sets stage for new physics era
M2 - Tue Feb 25, 8:45AM CST
Malignant Glioma - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/zr3vfj/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2013" report to their offering. 'Malignant Glioma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Malignant Glioma Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles Eir-060 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile Carboxyamidotriazole Orotate - Drug Profile SL-701 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile SAR-245409 - Drug Profile WT1 Peptide Vaccine - Drug Profile celecoxib Dendritic Cell Vaccine [temozolomide] Radiation Therapy - Drug Profile Dendritic Cell Vaccine - Drug Profile Peptide Vaccine [sargramostim] - Drug Profile ALD-451 - Drug Profile First Generation Attenuated Strain Of Reovirus - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Sanofi Cytomedix, Inc. Stemline Therapeutics, Inc. EirGen Pharma Ltd. Tactical Therapeutics, Inc For more information visit http://www.researchandmarkets.com/research/zr...ant_glioma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
W2 Energy Reports on 2013 and Looks Forward to 2014
Marketwire - Tue Jan 14, 1:06PM CST
W2 Energy, Inc. (OTC Pink: WTWO) is pleased to report on 2013's past year progress and looking forward into 2014.
Better Increase, Best Family, Fun Day for Eskom Workers [press release]
All Africa Global Media - Tue Jan 14, 12:38PM CST
The National Union of Mineworkers (NUM) is extremely saddened by Eskom for its failure to pay the salary increase of its employees "who have been unilaterally declared essential service by Eskom Management".
Cytomedix Announces Completion of RECOVER-Stroke Trial Enrollment and Update on Bright Cell Technology
Marketwire - Mon Jan 06, 7:02AM CST
Cytomedix, Inc. (OTCQX: CMXI), a leading developer of biologically active regenerative therapies, announced today the completed enrollment of the RECOVER-Stroke trial. Based on an interim resizing analysis that was performed on the existing population of all subjects who have reached the treatment plus 90 days primary efficacy endpoint, it was concluded that the ongoing RECOVER-Stroke trial is adequately powered based on pre-specified assumptions at the current enrollment of 48 patients. Consequently, additional screening and enrollment of new patient subjects will cease immediately. The Company expects to announce the top line clinical results in May 2014 when they become available.
